GUEST: Elisabeth de Vries, Groningen
In this episode we talk about nectin-4 - an emerging biomarker for cancer diagnosis and therapy - with one of the most influential and distinguished scientists in medical oncology, Elisabeth de Vries.
We talk about the first-in-human study of a radioligand that can target nectin-4 and learn what medical oncologists need to get out from imaging data so that these powerful tools continue to make an impact on patient outcomes.
We learn about the importance and best practices for robust clinical trials and the hurdles to both design and finance them.
Along the way, we get a glimpse into Elisabeth’s career path and how her research combines nuclear with optical imaging modalities as methods to improve patient diagnosis and treatment.

Selected Publication: "First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma" published in Clinical Cancer research by the authors X. Duan, L. Xia, Z. Zhang, Y. Ren, M. G. Pomper, S. P. Rowe, X. Li, N. Li, N. Zhang, H. Zhu 6, Z. Yang, X. Sheng, X. Yang (groups from Beijing University and Johns Hopkins University Baltimore).

Publication reference: Xiaojiang Duan, Lei Xia, Zhuochen Zhang, Yanan Ren, Martin G Pomper, Steven P Rowe, Xuesong Li, Nan Li, Ning Zhang, Hua Zhu 6, Zhi Yang, Xinan Sheng, Xing Yang. First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma. Clin Cancer Res. 2023 Apr 24;CCR-23-0609. doi: 10.1158/1078-0432.CCR-23-0609. https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-23-0609/726342/First-in-Human-Study-of-the-Radioligand-68Ga-N188

Further information on the European Society for Molecular Imaging:
https://e-smi.eu/
Contact: office@e-smi.eu